Hospital Universitari Vall d´Hebron | ClinicalTrials HQ

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer	HER2-positive Breast Cancer	Recruiting	Phase 2	2026-09-11		NCT05306041
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma	Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm	Active, not recruiting	Phase 3	2026-07-06		NCT05948475
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide	Newly Diagnosed Multiple Myeloma	Recruiting	Phase 3	2026-06-25		NCT05558319
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Solid Tumor, Adult	Recruiting	Phase 1 / Phase 2	2026-06-25		NCT04219254
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder	Recruiting	Phase 3	2026-02-05		NCT07389265
Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm	Active, not recruiting	Phase 2	2024-10-18		NCT05659914
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years	Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 3	2022-09-14		NCT03742297